Literature DB >> 12186922

The antiviral efficacy of the murine alpha-1 interferon transgene against ocular herpes simplex virus type 1 requires the presence of CD4(+), alpha/beta T-cell receptor-positive T lymphocytes with the capacity to produce gamma interferon.

Daniel J J Carr1, Sansanee Noisakran.   

Abstract

Alpha/beta interferons (IFN-alpha/betas) are known to antagonize herpes simplex virus type 1 (HSV-1) infection by directly blocking viral replication and promoting additional innate and adaptive, antiviral immune responses. To further define the relationship between the adaptive immune response and IFN-alpha/beta, the protective effect induced following the topical application of plasmid DNA containing the murine IFN-alpha 1 transgene onto the corneas of wild-type and T-cell-deficient mice was evaluated. Mice homozygous for both the T-cell receptor (TCR) beta- and delta-targeted mutations expressing no alpha beta or gamma delta TCR (alpha beta/gamma delta TCR double knockout [dKO]) treated with the IFN-alpha 1 transgene succumbed to ocular HSV-1 infection at a rate similar to that of alpha beta/gamma delta TCR dKO mice treated with the plasmid vector DNA. Conversely, mice with targeted disruption of the TCR delta chain and expressing no gamma delta TCR(+) cells treated with the IFN-alpha 1 transgene survived the infection to a greater extent than the plasmid vector-treated counterpart and at a level similar to that of wild-type controls treated with the IFN-alpha 1 transgene. By comparison, mice with targeted disruption of the TCR beta chain and expressing no alpha beta TCR(+) cells (alpha beta TCR knockout [KO]) showed no difference upon treatment with the IFN-alpha1 transgene or the plasmid vector control, with 0% survival following HSV-1 infection. Adoptively transferring CD4(+) but not CD8(+) T cells from wild-type but not IFN-gamma-deficient mice reestablished the antiviral efficacy of the IFN-alpha 1 transgene in alpha beta TCR KO mice. Collectively, the results indicate that the protective effect mediated by topical application of a plasmid construct containing the murine IFN-alpha 1 transgene requires the presence of CD4(+) T cells capable of IFN-gamma synthesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12186922      PMCID: PMC136437          DOI: 10.1128/jvi.76.18.9398-9406.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  83 in total

1.  Innate and acquired immunity to herpes simplex virus type 1.

Authors:  W P Halford; L A Veress; B M Gebhardt; D J Carr
Journal:  Virology       Date:  1997-09-29       Impact factor: 3.616

2.  Production of interferon-alpha/beta by murine dendritic cell lines stimulated by virus and bacteria.

Authors:  M L Eloranta; K Sandberg; P Ricciardi-Castagnoli; M Lindahl; G V Alm
Journal:  Scand J Immunol       Date:  1997-09       Impact factor: 3.487

3.  Absence of macrophage inflammatory protein-1alpha prevents the development of blinding herpes stromal keratitis.

Authors:  T M Tumpey; H Cheng; D N Cook; O Smithies; J E Oakes; R N Lausch
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Cytokine production in the nervous system of mice during acute and latent infection with herpes simplex virus type 1.

Authors:  C Shimeld; J L Whiteland; N A Williams; D L Easty; T J Hill
Journal:  J Gen Virol       Date:  1997-12       Impact factor: 3.891

Review 5.  Cellular responses to interferon-gamma.

Authors:  U Boehm; T Klamp; M Groot; J C Howard
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

6.  Interferon-gamma protects against herpes simplex virus type 1-mediated neuronal death.

Authors:  K D Geiger; T C Nash; S Sawyer; T Krahl; G Patstone; J C Reed; S Krajewski; D Dalton; M J Buchmeier; N Sarvetnick
Journal:  Virology       Date:  1997-11-24       Impact factor: 3.616

7.  Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.

Authors:  L A Morrison; D M Knipe
Journal:  Virology       Date:  1997-12-22       Impact factor: 3.616

8.  Anti-CD8 treatment alters interleukin-4 but not interferon-gamma mRNA levels in murine sensory ganglia during herpes simplex virus infection. Brief report.

Authors:  D C Tscharke; A Simmons
Journal:  Arch Virol       Date:  1999       Impact factor: 2.574

9.  T cell receptor-gamma/delta cells protect mice from herpes simplex virus type 1-induced lethal encephalitis.

Authors:  R Sciammas; P Kodukula; Q Tang; R L Hendricks; J A Bluestone
Journal:  J Exp Med       Date:  1997-06-02       Impact factor: 14.307

10.  Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response.

Authors:  K Goldsmith; W Chen; D C Johnson; R L Hendricks
Journal:  J Exp Med       Date:  1998-02-02       Impact factor: 14.307

View more
  10 in total

1.  Type I Interferons are essential for the efficacy of replicase-based DNA vaccines.

Authors:  Wolfgang W Leitner; Elke S Bergmann-Leitner; Leroy N Hwang; Nicholas P Restifo
Journal:  Vaccine       Date:  2006-05-06       Impact factor: 3.641

2.  Prolonged transgene expression with lentiviral vectors in the aqueous humor outflow pathway of nonhuman primates.

Authors:  Román A Barraza; Carol A Rasmussen; Nils Loewen; J Douglas Cameron; B'Ann T Gabelt; Wu-Lin Teo; Paul L Kaufman; Eric M Poeschla
Journal:  Hum Gene Ther       Date:  2009-03       Impact factor: 5.695

3.  Microglia and a functional type I IFN pathway are required to counter HSV-1-driven brain lateral ventricle enlargement and encephalitis.

Authors:  Christopher D Conrady; Min Zheng; Nico van Rooijen; Douglas A Drevets; Derek Royer; Anthony Alleman; Daniel J J Carr
Journal:  J Immunol       Date:  2013-02-04       Impact factor: 5.422

4.  The early interferon alpha subtype response in infant macaques infected orally with SIV.

Authors:  Juliet Easlick; Richard Szubin; Samantha Lantz; Nicole Baumgarth; Kristina Abel
Journal:  J Acquir Immune Defic Syndr       Date:  2010-09       Impact factor: 3.731

5.  Tumor necrosis factor (TNF) protects resistant C57BL/6 mice against herpes simplex virus-induced encephalitis independently of signaling via TNF receptor 1 or 2.

Authors:  Patric Lundberg; Paula V Welander; Carl K Edwards; Nico van Rooijen; Edouard Cantin
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

6.  Distinctive roles for 2',5'-oligoadenylate synthetases and double-stranded RNA-dependent protein kinase R in the in vivo antiviral effect of an adenoviral vector expressing murine IFN-beta.

Authors:  Khaldun Al-Khatib; Bryan R G Williams; Robert H Silverman; William Halford; Daniel J J Carr
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

7.  Consequences of CXCL10 and IL-6 induction by the murine IFN-alpha1 transgene in ocular herpes simplex virus type 1 infection.

Authors:  Stephanie Wickham; John Ash; Thomas E Lane; Daniel J J Carr
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

8.  Effect of anti-CXCL10 monoclonal antibody on herpes simplex virus type 1 keratitis and retinal infection.

Authors:  Daniel J J Carr; James Chodosh; John Ash; Thomas E Lane
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

9.  Loss of mandibular lymph node integrity is associated with an increase in sensitivity to HSV-1 infection in CD118-deficient mice.

Authors:  Christopher D Conrady; Manoj Thapa; Todd Wuest; Daniel J J Carr
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

10.  Rates of reactivation of latent herpes simplex virus from mouse trigeminal ganglia ex vivo correlate directly with viral load and inversely with number of infiltrating CD8+ T cells.

Authors:  Yo Hoshino; Lesley Pesnicak; Jeffrey I Cohen; Stephen E Straus
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.